Investors - Media Releases

Stay Informed

2010 2009 2008 2007 2006 2005 2004 2003

Back to list

April 26, 2010

mondoBIOTECH holding AG (SIX:RARE): board member Michael A. Keller elected a fellow at the American Academy of Arts and Sciences

Stans/Palo Alto, 26th April 2010 - Board member Michael A. Keller, Stanford University Librarian, Publisher, and Director Academic Computing as well as a prominent innovator and exploiter of Internet and World Wide Web technologies, has been elected a Fellow of the American Academy of Arts and Sciences. Founded during the American Revolution by John Adams, John Hancock and James Bowdoin and chartered in 1780, the Academy is an independent, nonpartisan policy research center devoted to the cultivation and advancement of the arts and sciences for the benefit of humanity. Keller is well positioned at Stanford to work with other Silicon Valley figures in technology and investment circles to engage in the sort of iterative innovation that has generated significant value propositions and distributable technologies. Consistent with the philosophy of Mondobiotech, the American Academy of Arts and Sciences engages independent, multidisciplinary analysis to study current issues facing society, from concerns about health and education to basic science to indicators from the humanities to public policy generation. Fundamental to the program of the American Academy of Arts and Sciences, as with Mondobiotech, are studies deriving from and benefitting individuals, whether through research programs revealing new possibilities in the basic and applied sciences, through government activity and services, through university and independent research, and through community engagement. Already a Fellow of the American Association for the Advancement of Science, Keller believes that “fellowships such as these provide privileged access to leading thinkers and actors from numerous disciplines and settings result in cross fertilization of ideas. These interdisciplinary encounters generate new hypotheses, new solutions, and new approaches to human concerns, a specific example of which is the nexus of scientific, community, and business models of Mondobiotech.” Added Mondobiotech CEO and co-founder Fabio Cavalli, “Mr. Keller’s election to the American Academy of Arts and Sciences underscores his expertise in his field, and once again demonstrates that Mondobiotech’s team is in a very strong position to effectuate the changes we wish to see in the world of medicine. We continue to move forward with the most innovative people and technologies we can acquire. We are very pleased and proud that Mr. Keller has received this honor for his many years of excellent work in his field.” About Mondobiotech mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases. For further information please contact: mondoBIOTECH holding AG Das Kloster Mürgstrasse 18 CH-6370 Stans Tel.: +41 (0) 840 200 010 Fax: +41 (0) 840 200 011 press@mondobiotech.com www.mondobiotech.com Disclaimer The foregoing release may contain forward-looking statements. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG’s forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward- looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. mondoBIOTECH holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. Personal Information This email is from mondoBIOTECH holding AG. The email and any files transmitted with it are intended solely for the use of the individual or entity to which they are addressed. Any unauthorized dissemination or copying of this email or its attachments, is strictly prohibited and may be illegal. If you have received the email in error please delete it from your system. Download the Newsletter in pdf format

Back to list